Select Publications

Journal articles

Labbouz S; Khan S; Gohara M; Lucas J; Sarkar R; Murrell DF; Dodiuk-Gad RP, 2024, 'Meeting report: Women’s Dermatology Society Forum at the 25th World Congress of Dermatology, Singapore, 2023', International Journal of Women's Dermatology, 10, http://dx.doi.org/10.1097/JW9.0000000000000125

Navarrete-Dechent C; Ashique KT; Ingram JR; Rudnicka L; Gilaberte Y; Ring J; Murrell DF; Elston D; Thiers BH, 2024, 'The road to publication: Advice from journal editors', Journal of the American Academy of Dermatology, http://dx.doi.org/10.1016/j.jaad.2023.11.038

Guttman-Yassky E; Bahadori L; Brooks L; Clark KL; Grindebacke H; Ho CN; Katial R; Pham TH; Walton C; Datto CJ, 2023, 'Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1211 - e1214, http://dx.doi.org/10.1111/jdv.19195

Kircik LH; Alonso-Llamazares J; Bhatia N; Bukhalo M; Devani AR; Draelos ZD; Dubois J; Gooderham MJ; Kempers SE; Lain E; Lee M; Moore A; Murrell DF; Papp KA; Pariser DM; Sinclair R; Zirwas M; Burnett P; Higham RC; Krupa D; Berk DR, 2023, 'Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study', British Journal of Dermatology, 189, pp. 392 - 399, http://dx.doi.org/10.1093/bjd/ljad182

Yale M; Dunn P; Strong R; Davies I; Gallu L; Joly P; Murrell DF; Werth VP; Payne AS, 2023, 'The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid', Journal of Investigative Dermatology, 143, pp. 1868 - 1871, http://dx.doi.org/10.1016/j.jid.2023.03.1673

Wilson BN; Shah R; Sun MD; Diaz AF; Murrell DF; Murase JE, 2023, 'Evaluation of skin of color publication trends over the past 2 decades in the Journal of the American Academy of Dermatology', Journal of the American Academy of Dermatology, 89, pp. 614 - 616, http://dx.doi.org/10.1016/j.jaad.2023.05.036

Singh S; Kirtschig G; Anchan VN; Chi CC; Taghipour K; Boyle RJ; Murrell DF, 2023, 'Interventions for bullous pemphigoid', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD002292.pub4

Wang MA; Wilson A; Murrell DF, 2023, 'A Review of the Scoring and Assessment of Keratosis Pilaris', Skin Appendage Disorders, 9, pp. 241 - 251, http://dx.doi.org/10.1159/000529487

Mosallaei D; Murrell DF; Grant-Kels JM, 2023, 'Dermatoethics: Nepotism in dermatology residencies', Journal of the American Academy of Dermatology, 89, pp. 193 - 194, http://dx.doi.org/10.1016/j.jaad.2022.01.011

Silverberg JI; Bissonnette R; Kircik L; Murrell DF; Selfridge A; Liu K; Ahluwalia G; Guttman-Yassky E, 2023, 'Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1366 - 1374, http://dx.doi.org/10.1111/jdv.18914

Patel NJ; Jayne DRW; Merkel PA; Bekker P; Zhang Y; McDowell PJ; Johal J; Heaney LG; Murrell D; Stone MN; Yue H; Stone JH, 2023, 'The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial', The Lancet Rheumatology, 5, pp. e413 - e421, http://dx.doi.org/10.1016/S2665-9913(23)00131-5

Murrell D; L. Bruckner A; Sprecher E; Kiritsi D; Maher L; Cunningham T; Kern JS, 2023, 'BG04 Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study', British Journal of Dermatology, 188, http://dx.doi.org/10.1093/bjd/ljad113.144

Teng J; Paller AS; Bruckner AL; Murrell DF; Mellerio JE; Bodemer C; Martinez AE; Lugo-Somolinos A; Sprecher E; Laimer M; Wally V; Chan YM; Lin SY; Spellman M; Bauer JW, 2023, 'Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial', Journal of Drugs in Dermatology, 22, pp. 599 - 604, http://dx.doi.org/10.36849/JDD.7108

Murrell DF; Teng JMC; Guenthner S; Marathe K; Kempers S; Eads K; Castelo-Soccio L; Mendelsohn AM; Raiz J; Bunick CG, 2023, 'Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis', Clinical and Experimental Dermatology, 48, pp. 623 - 630, http://dx.doi.org/10.1093/ced/llad033

Cowan TL; Ho G; Daniel BS; Murrell DF, 2023, 'Use of a hybrid teledermatology model in an Australian tertiary hospital during the COVID-19 pandemic', JAAD International, 11, pp. 33 - 34, http://dx.doi.org/10.1016/j.jdin.2022.03.016

Lee H; Cowan TL; Daniel BS; Murrell DF, 2023, 'A review of JAK and IL-23 inhibitors to treat vitiligo', Australasian Journal of Dermatology, 64, pp. 204 - 212, http://dx.doi.org/10.1111/ajd.14001

Wilson A; Tariq Khan M; Murrell DF, 2023, 'Median canaliform nail dystrophy in a 2-year-old boy: Case report and review of the literature', Pediatric Dermatology, 40, pp. 511 - 518, http://dx.doi.org/10.1111/pde.15181

Aung T; Noakes R; Murrell DF; Daniel BS; Kelati A, 2023, 'Primary cutaneous amyloidosis: A review of the available studies and gaps in data', Australasian Journal of Dermatology, 64, pp. e121 - e124, http://dx.doi.org/10.1111/ajd.14012

Johal JS; Cowan TL; Murrell DF, 2023, 'Evaluating the nature and prevalence of glucocorticoid-induced type 2 diabetes mellitus in patients with autoimmune bullous diseases', Clinical and experimental dermatology, 48, pp. 448 - 452, http://dx.doi.org/10.1093/ced/llac137

Williams TG; Hackett LM; Lam PH; Stitz DJ; Al-Housni H; Murrell DF; Murrell GAC, 2023, 'Fibrillar matrix, Echogenicity, Contour, Thickness, and Suture (FECTS) vs. Global: A comparison of 2 scales developed to assess ultrasound images post rotator cuff repair', Journal of Shoulder and Elbow Surgery, 32, pp. 713 - 728, http://dx.doi.org/10.1016/j.jse.2022.10.035

Tully JM; Murase JE; Grant-Kels JM; Murrell DF, 2023, 'Gender Equity in Medicine and Dermatology in the United States: The Long Road Traveled and the Journey ahead', Dermatologic Clinics, 41, pp. 265 - 278, http://dx.doi.org/10.1016/j.det.2022.08.007

Xie D; Bilgic A; Abu Alrub N; Dicle Ö; Murrell DF, 2023, 'Clinical manifestations of alopecia in autoimmune blistering diseases: A cross-sectional study', JAAD International, 10, pp. 6 - 13, http://dx.doi.org/10.1016/j.jdin.2022.08.025

Wilson A; Cowan TL; Rivero ADL; Murrell DF, 2023, 'The dangers of social media: patients with atopic dermatitis ceasing their basic treatment', Clinical and Experimental Dermatology, 48, pp. 142 - 143, http://dx.doi.org/10.1093/ced/llac056

COWAN T; ABU ALRUB N; WİLSON A; MAKHİJA M; MURRELL D, 2023, 'Eksfolyatif keilit tedavisinde tildrakizumab', Mucosa, 6, pp. 19 - 21, http://dx.doi.org/10.33204/mucosa.1209480

Murrell DF; Joly P; Werth VP; Laws E; Mannent LP; Beazley B; Dubost-Brama A; Shabbir A, 2023, '307 The study design of a trial of dupilumab in adult patients with bullous pemphigoid (BP): LIBERTY-BP ADEPT', British Journal of Dermatology, 188, http://dx.doi.org/10.1093/bjd/ljac140.007

Hundt JE; Sadik CD; van Beek N; Busch H; Caux F; Goebeler M; Hammers CM; Hartmann K; Hashimoto T; Ibrahim S; Kasperkiewicz M; Murrell DF; Recke A; Rose C; Schumacher N; Shimanovich I; Sitaru C; Terheyden P; Thaçi D; Ludwig RJ; Schmidt E, 2023, 'A life for autoimmune blistering diseases: in memoriam Detlef Zillikens', Frontiers in Immunology, 14, http://dx.doi.org/10.3389/fimmu.2023.1291590

Koszegi B; Stone C; Murrell DF, 2023, 'Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia', Frontiers in Medicine, 10, http://dx.doi.org/10.3389/fmed.2023.1149742

Patsatsi A; Daneshpazhooh M; Tavakolpour S; Mahmoudi H; Murrell DF, 2023, 'Editorial: Challenges of COVID-19 in dermatology patients on immunosuppression: risk, outcome, vaccination and beyond, volume II', Frontiers in Medicine, 10, http://dx.doi.org/10.3389/fmed.2023.1268285

Kern JS; Sprecher E; Fernandez MF; Schauer F; Bodemer C; Cunningham T; Löwe S; Davis C; Sumeray M; Bruckner AL; Murrell DF, 2023, 'Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study', British Journal of Dermatology, 188, pp. 12 - 21, http://dx.doi.org/10.1093/bjd/ljac001

Rodriguez R; Sivesind TE; Murrell D; Dellavalle RP, 2023, 'From the Cochrane Library: Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus', JMIR Dermatology, 6, http://dx.doi.org/10.2196/46812

Huang C; Bullpitt P; Nabarrro M; Murrell DF, 2023, 'Practice Dilemma: Expanding Melanonychia in the Paediatric Setting', Skin Appendage Disorders, 9, pp. 58 - 60, http://dx.doi.org/10.1159/000526102

Johal J; Cowan T; Bilgic A; Bozca B; Enli S; Yang B; Daneshpazhooh M; Boziou M; Patsatsi A; Mundin C; Quizon M; Kakuta R; Takahashi H; Wilson A; Zeng F; Murrell D, 2023, '390 Examining the risk factors for worsened glucocorticoid morbidity in a prospective, multicentre, international study of patients with autoimmune blistering diseases', Journal of Investigative Dermatology, 143, pp. S67 - S67, http://dx.doi.org/10.1016/j.jid.2023.03.396

Wang MA; Wilson A; Daniel B; Rivero ADL; Martin L; Kern JS; Murrell D, 2023, '396 A novel investigator global assessment score for the evaluation of keratosis pilaris', Journal of Investigative Dermatology, 143, pp. S68 - S68, http://dx.doi.org/10.1016/j.jid.2023.03.402

Tada Y; Takeoka S; Spelman L; Murrell D; Chu C; Chung W; Wu J; Zoob P; Bosman K, 2023, '459 Demographics, comorbidities and disease severity before dupilumab treatment initiation in Asian patients with atopic dermatitis', Journal of Investigative Dermatology, 143, pp. S79 - S79, http://dx.doi.org/10.1016/j.jid.2023.03.465

Joly P; Patel HV; Cella RR; Kephart L; Murrell D, 2023, '639 Design of marigold-bp: A phase 2/3 study of nipocalimab in adults with moderate to severe bullous pemphigoid', Journal of Investigative Dermatology, 143, pp. S109 - S109, http://dx.doi.org/10.1016/j.jid.2023.03.646

Bai H; Lin G; Kantor J; Elston D; Grant-Kels JM; Murrell DF; Murase JE, 2023, 'Dermatology Journal Advisory Boards and Editorial Independence', JAAD International, http://dx.doi.org/10.1016/j.jdin.2023.08.001

Schmidt E; Diaz LA; Amagai M; Murrell DF, 2023, 'Detlef Zillikens, 1958-2022', Journal of Investigative Dermatology, 143, pp. 7 - 8, http://dx.doi.org/10.1016/j.jid.2022.11.001

Keller Rosenthal N; Boucher D; Murrell DF, 2022, 'The efficacy of adding oral sodium cromoglycate to stable treatment for controlling bullous pemphigoid-related pruritus: A retrospective study', Frontiers in Medicine, 9, http://dx.doi.org/10.3389/fmed.2022.1051804

So JY; Fulchand S; Wong CY; Li S; Nazaroff J; Gorell ES; de Souza MP; Murrell DF; Teng JM; Chiou AS; Tang JY, 2022, 'A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex', Orphanet Journal of Rare Diseases, 17, http://dx.doi.org/10.1186/s13023-022-02433-3

Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF, 2022, 'A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa', Orphanet Journal of Rare Diseases, 17, http://dx.doi.org/10.1186/s13023-022-02461-z

Vermeer MCSC; Al-Shinnag M; Silljé HHW; Gaytan AE; Murrell DF; McGaughran J; Melbourne W; Cowan T; van den Akker PC; van Spaendonck-Zwarts KY; van der Meer P; Bolling MC, 2022, 'A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradation', British Journal of Dermatology, 187, pp. 1045 - 1048, http://dx.doi.org/10.1111/bjd.21832

Mazaherpour E; Kianfar N; Dasdar S; Sedaghat M; Seyrafi H; Balighi K; Saberi F; Nili A; Farimani Z; Azar PM; Mahmoodi H; Murrell DF; Daneshpazhooh M, 2022, 'Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab-treated and rituximab-naïve patients', Dermatologic Therapy, 35, http://dx.doi.org/10.1111/dth.15902

Ho G; Gibson M; Kazemikhoo N; Murrell DF, 2022, 'Long-term follow-up of epidermolysis bullosa in real practice shows stability of the Epidermolysis Bullosa Disease Activity and Scarring Index and improvement with some off-label therapies', JAAD International, 9, pp. 105 - 107, http://dx.doi.org/10.1016/j.jdin.2022.07.008

Lee BWH; Taylor SF; Gal A; Murrell DF; Coroneo MT, 2022, 'Sebaceous cell carcinoma presenting as ocular Marjolin ulcer following immunosuppression for a chemical burn', Canadian Journal of Ophthalmology, 57, pp. e206 - e208, http://dx.doi.org/10.1016/j.jcjo.2022.02.023

Zeng FAP; Wilson A; Sheriff T; Murrell DF, 2022, 'Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review', JAAD International, 9, pp. 33 - 43, http://dx.doi.org/10.1016/j.jdin.2022.07.005

Teng JMC; Bunick CG; Guenthner S; Murrell DF; Marathe K; Kempers S; Eads K; Mendelsohn AM; Raiz J; Tavakkol A; Castelo-Soccio L, 2022, 'The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis', Journal of the American Academy of Dermatology, 87, pp. 1455 - 1458, http://dx.doi.org/10.1016/j.jaad.2022.07.028

Zeng FAP; Murrell DF, 2022, 'Bullous pemphigoid—What do we know about the most recent therapies?', Frontiers in Medicine, 9, http://dx.doi.org/10.3389/fmed.2022.1057096

Bilgic A; Murrell DF, 2022, 'Designing the Future of Dermatology and Venereology', EMJ Dermatology, pp. 18 - 19, http://dx.doi.org/10.33590/emjdermatol/10176803

Karakioulaki M; Murrell DF; Kyriakou A; Patsatsi A, 2022, 'Investigation of comorbid autoimmune diseases in women with autoimmune bullous diseases: An interplay of autoimmunity and practical implications', International Journal of Women's Dermatology, 8, http://dx.doi.org/10.1097/JW9.0000000000000053

Murrell DF; Patsatsi A; Stavropoulos P; Baum S; Zeeli T; Kern JS; Sinclair R; Neale A; Arora P; Sugerman PB; Shi G; Werth VP; Caux F; Joly P; Patsatsi A; Sinclair R; Neale A; Arora P; Sugerman PB; Shi G; Werth VP; Caux F; Joly P; Stavropolous P; Baum S, 2022, 'Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris', Journal of the European Academy of Dermatology and Venereology, 36, pp. 852 - 855, http://dx.doi.org/10.1111/jdv.18318


Back to profile page